Praxis Precision Medicines, Inc. 8K

Praxis Precision Medicines announced positive FDA regulatory progress and launch preparations for ulixacaltamide and relutrigine, an additional Breakthrough Therapy Designation for elsunersen, mixed clinical results for vormatrigine, and a reinforced cash runway into 2028 in its second quarter 2026 update.

On August 6, 2026, Praxis Precision Medicines, Inc. reported its second quarter 2026 financial results and provided a broad corporate update, highlighting FDA mid‑cycle meetings for ulixacaltamide HCl (Essential Tremor) and relutrigine (SCN2A and SCN8A developmental and epileptic encephalopathies) with no major safety or efficacy concerns identified and no advisory committee meetings planned, updated PDUFA dates of January 29, 2027 for ulixacaltamide and December 27, 2026 for relutrigine following a major amendment to the relutrigine NDA, successful FDA Bioresearch Monitoring inspections with no Form 483 observations, acceleration of commercial launch preparations for both lead programs, receipt of Breakthrough Therapy Designation for elsunersen based on the EMBRAVE Part A trial, continued development of vormatrigine despite a Phase 2/3 primary endpoint miss, and a strengthened cash position of approximately $1.4 billion as of June 30, 2026 providing expected operating runway into 2028 despite a quarterly net loss of $83.7 million.

Filing Facts

CIK

1689548

Ticker

PRAX

Form

8K

Source Type

fda

Accession

0001689548-26-000082

Alert Tier

7